Cargando…

The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma.

We describe melphalan pharmacokinetics in 26 patients treated by isolated limb perfusion (ILP). Group A (n = 11) were treated with a bolus of melphalan (1.5 mg kg-1), and in a phase I study the dose was increased to 1.75 mg kg-1. The higher dose was given as a bolus to Group B (n = 9), and by divide...

Descripción completa

Detalles Bibliográficos
Autores principales: Scott, R. N., Kerr, D. J., Blackie, R., Hughes, J., Burnside, G., MacKie, R. M., Byrne, D. S., McKay, A. J.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1992
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977921/
https://www.ncbi.nlm.nih.gov/pubmed/1637666